γδ T细胞对造血干细胞移植临床结局的影响:系统综述与meta分析
该系统综述与meta分析检索截至2019年3月的文献,纳入11项研究共919例异基因造血干细胞移植患者,评估移植后γδ T细胞水平与复发、感染、生存及急性移植物抗宿主病(aGVHD)的关联。结果显示高γδ T细胞水平与较少复发、较少病毒感染及更高总生存和无病生存相关,但与aGVHD发生率无关联。
要点
- 移植后高γδ T细胞水平与疾病复发风险降低相关(RR 0.58)。
- 高γδ T细胞水平与病毒感染减少及总生存、无病生存改善相关。
- 高γδ T细胞水平与aGVHD发生率无显著关联。
核心结论
- 造血干细胞移植后高γδ T细胞水平与有利的临床结局相关,但与aGVHD发生无关,提示γδ T细胞对移植成功有显著影响。
研究设计与样本
- 系统综述与meta分析,检索PubMed、Web of Science、Scopus及会议摘要至2019年3月,最终纳入11项研究共919例患者。
- 采用随机效应模型合并结局,主要结局为疾病复发,同时评估感染、生存及aGVHD发生率,研究已注册于PROSPERO(CRD42019133344)。
主要发现
- 移植后高γδ T细胞值与较少疾病复发相关(RR 0.58;95%CI 0.40-0.84;P=.004;I2=0%)。
- 高γδ T细胞值与较少病毒感染相关(RR 0.59;95%CI 0.43-0.82;P=.002;I2=0%)。
- 高γδ T细胞值与更高的总生存(HR 0.28;95%CI 0.18-0.44;P<.00001;I2=0%)和无病生存(HR 0.29;95%CI 0.18-0.48;P<.00001;I2=0%)相关。
- 高γδ T细胞值与aGVHD发生率无关联(RR 0.72;95%CI 0.41-1.27;P=.26;I2=0%)。
临床怎么用
- 移植后监测γδ T细胞水平可能有助于评估复发、感染及生存风险,但尚不能据此常规干预aGVHD。
局限性
- 纳入研究数量有限(11项,919例),中位随访30个月(四分位距22-32),证据强度受原始研究异质性及设计限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) using αβ T-/B-cell-depleted grafts recently emerged as a transplant strategy and highlighted the potential role of γδ T cells on HSCT outcomes. Our aim was to scrutinize available evidence of γδ T-cell impact on relapse, infections, survival, and acute graft-versus-host disease (aGVHD). We performed a systematic review and meta-analysis of studies assessing γδ T cells in HSCT. We searched PubMed, Web of Science, Scopus, and conference abstracts from inception to March 2019 for relevant studies. We included all studies that assessed γδ T cells associated with HSCT. Data were extracted independently by 2 investigators based on strict selection criteria. A random-effects model was used to pool outcomes across studies. Primary outcome was disease relapse. We also assessed infections, survival, and aGVHD incidence. The review was registered with PROSPERO (CRD42019133344). Our search returned 2412 studies, of which 11 (919 patients) were eligible for meta-analysis. Median follow-up was 30 months (interquartile range, 22-32). High γδ T-cell values after HSCT were associated with less disease relapse (risk ratio [RR], 0.58; 95% confidence interval [95% CI], 0.40-0.84; P = .004; I2 = 0%), fewer viral infections (RR, 0.59; 95% CI, 0.43-0.82; P = .002; I2 = 0%) and higher overall (HR, 0.28; 95% CI, 0.18-0.44; P < .00001; I2 = 0%) and disease-free survivals (HR 0.29; 95% CI, 0.18-0.48; P < .00001; I2 = 0%). We found no association between high γδ T-cell values and aGVHD incidence (RR, 0.72; 95% CI, 0.41-1.27; P = .26; I2 = 0%). In conclusion, high γδ T cells after HSCT is associated with a favorable clinical outcome but not with aGVHD development, suggesting that γδ T cells have a significant effect on the success of HSCT. This study was registered with PROSPERO as #CRD42019133344.
引用
- Arruda LCM, Gaballa A, Uhlin M, et al. Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis. Blood Adv. 2019. PMID: 31714966. doi:10.1182/bloodadvances.2019000682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。